Ramucirumab combined with paclitaxel as the second-line chemotherapy for elderly patients with disseminated gastric cancer
https://doi.org/10.21518/2079-701X-2018-10-169-171
Abstract
Gastric cancer is the third leading cause of cancer-related deaths worldwide. The prognosis of advanced gastric cancer remains poor despite therapeutic advances in recent decades. Several recent positive phase III trials established the efficacy of second-line chemotherapy for metastatic gastric cancer in prolonging overall survival. Many targeted-therapies failed to show a significant survival benefit in GC, only 2 of them are approved FDA: trastuzumab in the 1-st line treatment of HER2-positive gastric cancer and ramucirumab with or without paclitaxel as second line chemotherapy. The article presents the case of effective treatment of patient with Her2-negative advanced gastric cancer. A 76-year-old man had a moderately differentiated adenocarcinoma of gastric with synchronous multiple liver metastases. He received ramucirumab with paclitaxel as second -line chemotherapy. The size of the liver metastases was reduced and he maintained a partial response for one year. This clinical case report demonstrates that new option in the treatment of advanced gastric cancer can to allow our patients to live longer without losing the quality of life.
About the Authors
T. A. Titova
N.N.Blokhin Russian Cancer Research Centre, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
N. S. Besova
N.N.Blokhin Russian Cancer Research Centre, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD In Medicine
Moscow
V. A. Gorbunova
N.N.Blokhin Russian Cancer Research Centre, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, Prof.
Moscow
R. N. Nasyrova
N.N.Blokhin Russian Cancer Research Centre, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in Medicine
Moscow
A. A. Fedenko
N.N.Blokhin Russian Cancer Research Centre, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD
Moscow
References
1. Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. Journal of surgical oncology, 2013, 107(3): 230-236.
2. Malignant neoplasms in Russia in 2014 (morbidity and mortality). Edited by Caprina AD, Starinsky VV, Petrova GV. Moscow: RIIS FIAN, 2016. 249 p.
3. Global Cancer Facts & Figures. 3rd ed. American Cancer Society. Available at: http:// www.cancer.org/acs/groups/content/@ research/documents/document/acspc-044738. pdf.
4. Kang JH, Lee SI, Lim do H et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol, 2012, 30(13): 1513-8.
5. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, Vita FD, Galizia G. Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients. Ann Surg Oncol, 2007, 15: 69–79.
6. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol, 2014, 15(11): 1224-35.
Review
For citations:
Titova TA, Besova NS, Gorbunova VA, Nasyrova RN, Fedenko AA. Ramucirumab combined with paclitaxel as the second-line chemotherapy for elderly patients with disseminated gastric cancer. Meditsinskiy sovet = Medical Council. 2018;(10):169-171. (In Russ.) https://doi.org/10.21518/2079-701X-2018-10-169-171
Views:
1003
Email this article 